NCT03934372 2025-12-17Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsIncyte CorporationPhase 1/2 Recruiting70 enrolled
NCT04233346 2025-04-04The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I MutationOtsuka Beijing Research InstitutePhase 2 Active not recruiting93 enrolled
NCT01667133 2022-06-13A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)TakedaPhase 1/2 Completed35 enrolled 36 charts
NCT00660920 2018-05-16Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological MalignanciesTakedaPhase 1 Completed81 enrolled
NCT01650805 2014-11-17Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Ariad PharmaceuticalsPhase 3 Terminated307 enrolled 11 charts